NCT02245204已完成1 期
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Number of adverse events
研究概览
简要总结
The purpose of this study:
Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced malignant tumor subjects;
详细描述
- Investigate the tolerance of Chlorogenic acid for injection in human body, determine the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for injection in the advanced malignant tumor subjects;
- Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection;
- Preliminary observation the effectiveness and effective dose;
- Provide the basis for the dosage regimen of phase II/III.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with pathologic or/and FNAC confirmation of advanced cancer but without effective treatment or with treatment failure;
- •Between 18 and 65 years of age, KPS≥70;
- •According to RECIST 1.1,patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as >2.0cm by general CT or >1.0cm by spiral CT;
- •Life expectancy of at least three (3) months at the enrollment;
- •Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:
- •PLT count≥100×10~9/L,
- •WLB count≥4.0×10~9/L and ≤12×10~9/L,
- •Neutrophil granulocyte count≥2.0×10~9/L,
- •HGB count≥90g/L,
- •Total bilirubin <=1.5 times of ULN,
- •ALT/AST ≤2.5 times of ULN,
- •SCr≤1.5 times of ULN,
- •Normal ECG with LVEF (≥50%) measured by echocardiography;
- •Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months;
- •Volunteered for the phase 1 trial and sign the informed consent without protest;
排除标准
- •Patients who have received large area radiotherapy （>30% marrow capacity）;
- •Patients who suffer from other serious complication, such as uncontrollable infection, myocardial infarction within the past 6 months at the enrollment , uncontrollable hypertension ,thromboembolism and etc.;
- •Symptomatic patients with brain metastases (except for the patients whose brain metastases is controlled to stable status after whole brain radiotherapy);
- •Patients who have received the therapy of chemotherapy within 4 weeks before enrollment;
- •Patients who have used nitrosoureas drug or mitomycin within 6 weeks or tyrosine kinase inhibitor within 2 weeks before enrollment;
- •Patients who have received therapy of major surgery within 6 weeks or biopsy surgery within 2 weeks before enrollment;
- •Patients who or have received radical radiotherapy within 6 weeks or local palliative radiotherapy within 2 weeks before enrollment;
- •Patients who experience grade 2 or more than grade 2 toxicity caused by the past therapies;
- •Patients who have history of drug abuse or alcoholism;
- •Patients who smoke over 5 cigarettes or equivalent tobacco per day;
- •Uncontrollable psychopaths;
- •Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;
- •Patients who had received a therapy of another investigational drug within 4 weeks or patients who are still in another clinical trial at the enrollment;
- •Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;
- •Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters;
- •Allergic to the investigational drug;
- •Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).
研究组 & 干预措施
Chlorgenic acid, Treatment, powder
Experimental
Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
干预措施: Chlorogenic acid (Drug)
结局指标
主要结局
Number of adverse events
时间窗: Within the first 60 days after the first dose of chlorogenic acid
次要结局
- Dose-Limiting Toxicity(Within the first 30 days after the first dose of chlorogenic acid)
- Maximum Tolerated Dose(Within the first 30 days after the first dose of chlorogenic acid)
- Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of chlorogenic acid(Within the first 30 days after the first dose of chlorogenic acid)
- Improvement in cancer-related symptoms and quality of life(Within 1 year after the first dose of chlorogenic acid)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM PatientsGBMNCT03758014Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd200
已完成
1 期
Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced GlioblastomaGlioblastomaNCT02728349Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd26
终止
1 期
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory CancerNeoplasmsNCT00547261Sanofi6
已完成
1 期
Safety and Pharmacokinetic Profile of CKD-581Multiple MyelomaLymphomaNCT01580371Chong Kun Dang Pharmaceutical39
Unknown
1 期
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma PatientsHigh-grade GliomasNCT03904628Lee's Pharmaceutical Limited15